Clinical Trial

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases
Trial Details
NCT Number NCT06218888
Lead Sponsor Fujian Cancer Hospital
Conditions Colo-rectal Cancer
Enrollment 17 participants
Start Date 2024-06-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-23